TNBC, which lacks estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression, accounts for 10–20% of all breast cancers and is associated with a poor prognosis due to its aggressive nature and limited treatment options [3]. This evidence concerns the gene ERBB2 and breast cancer.